Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

and development expenses for the year ended December 31, 2008 totaled $46.5 million compared with $38.9 million in 2007. Research and development expenses were $13.9 million for the three months ended December 31, 2008 compared to $9.3 million for the same quarter the previous year. The increase in expenses was the net result of: achieving full enrolment of clinical sites and patients in the MAESTRO-03 trial; increased costs for the MAESTRO-02 trial as patients enter the trial; reduced costs of the MAESTRO-01 and MINDSET-01 trials as more patients complete these trials; a decrease in drug manufacturing expenses as the manufacture of validation batches is completed; a licensing bonus payment related to the Agreement with Lilly, and; additional expenses related to alliance management and support.

At December 31, 2008, cash and cash equivalents and short-term investments totaled $90.4 million as compared to $37.9 million at December 31, 2007. At December 31, 2008, the Company had working capital of $81.3 million as compared to $32.8 million at December 31, 2007. Management estimates that the current working capital is sufficient for the Company to meet its obligations in respect of the currently initiated clinical trials.

As at December 31, 2008 there were 91,009,323 Class "A" common shares of the Company issued and outstanding.

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchan
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , Sept. 3, 2015 /PRNewswire/ - bioLytical Laboratories Inc., ... announce its study " Sensitivity of a rapid point ... enhanced by its affinity for HIV gp41 IgM antibodies ... Virology.  This study highlights INSTI,s ability to detect early ... findings at the 8 th annual International AIDS ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... non-invasive hydration monitoring wearable early 2016. , The device, called the Halo ... proprietary optical and electrical sensing technology. These sensors track trending interstitial fluid levels ...
(Date:9/2/2015)... ARBOR, Mich. and LIBERTYVILLE, Ill. (PRWEB) , ... ... ... NSF International, a leading provider of regulatory compliance, quality systems, analytical ... Avarent LLC, a consulting firm with expertise in medical device products/processes development, ...
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... Companies" to their offering. This ... as a characteristic that can be objectively measured ... or pathogenic processes as well as pharmacological responses ...
Breaking Biology Technology:bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 2bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 3Technology Startup Halo Wearables to Unveil Non-Invasive Hydration Monitoring Device Early 2016 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3
... 31, 2008 at 11:00 a.m. EDT, NEW ... China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin ... branded,bio-pharmaceutical products in China, today announced it will ... on Monday 31, 2008. In,conjunction, the Company will ...
... International,Corporation (Nasdaq: PRXL ) will release Third Quarter ... after the close of the stock,market. The announcement will ... on the PR Newswire website at http://www.prnewswire.com ... live webcast at 10:00 a.m. EDT,on Thursday, April 24, ...
... Therapeutics, LLC, an,oncology-focused, clinical-stage, biopharmaceutical company, announced ... and Development, is,scheduled to present at Cambridge ... March 28st at 1:35 p.m. PST at ... Dr. Rao will focus on,considerations that are ...
Cached Biology Technology:China Pharma Holdings, Inc. Announces Earnings Call for Fiscal 2007 Financial Results 2PAREXEL Announces Date of Third Quarter Fiscal Year 2008 Earnings Release and Conference Call 2
(Date:8/18/2015)... Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ) ... Biometric Authentication & Identification Market: Focus On Modality, ... report to their offering. ... is expected to grow at an estimated CAGR ... over $25 billion (approximately) by 2020 as per ...
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that four of its ... solution, have officially been named FIDO Certified™ by ... of the certification, Synaptics, Natural ID™ fingerprint solutions ... Authentication Framework (UAF) standard and are interoperable among ...
(Date:8/6/2015)... Germany , August 6, 2015 /PRNewswire/ ... SensoMotoric Instruments (SMI) shows the world,s first ... based on Epson,s Moverio BT-200 see-through head mounted display ... new solution, unprecedented quality and efficiency is brought to ... displays. For the first time, professionals and researchers can ...
Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... 2011) Proving that technological entrepreneurship can have ... fields, renowned innovator, materials scientist and applied physicist ... recipient of the 2011 $500,000 Lemelson-MIT Prize. Rogers, ... products integral to human health, fiber optics, semiconductor ...
... A new study provides support for Darwin,s hypothesis ... more closely related species than those distantly related. ... study contains the strongest direct experimental evidence yet ... species extinction occurred more frequently and more rapidly ...
... rapidly spreading amphibian disease, has reached a site near ... the entire mountainous neotropics to be free of the ... Rescue and Conservation Project, a consortium of nine U.S. ... of frogs in imminent danger of extinction. ...
Cached Biology News:Materials scientist and entrepreneur Dr. John Rogers awarded $500,000 Lemelson-MIT Prize 2Materials scientist and entrepreneur Dr. John Rogers awarded $500,000 Lemelson-MIT Prize 3Materials scientist and entrepreneur Dr. John Rogers awarded $500,000 Lemelson-MIT Prize 4New study supports Darwin's hypothesis on competition between species 2New study supports Darwin's hypothesis on competition between species 3Scientists find deadly amphibian disease in the last disease-free region of central America 2Scientists find deadly amphibian disease in the last disease-free region of central America 3
Request Info...
Goat polyclonal to Factor VIII, prediluted ( Abpromise for all tested applications). Antigen: Full length native protein (purified) (Human): Factor VIII from blood. Entrez GeneID: 2157 Sw...
Anti-Bcl-G (CT) Host: rabbit polyclonal Species Reactivity: human, mouse, rat Applications: WB, IHC Storage: 4C...
Affinity Purified Rabbit Anti-mouse sRANKL Biotinylated Polyclonal Antibody...
Biology Products: